Cargando…

LGG-12. CLINICAL AND MOLECULAR FEATURES OF DISSEMINATED PEDIATRIC LOW-GRADE GLIOMA

Although most pediatric LGG (PLGG) have excellent long-term survival, there is a subset of cases that disseminate throughout the neuraxis (DLGG) that have very poor outcomes. The reason for this aggressive behavior is unknown but we hypothesize that distinct and specific biological mechanisms underl...

Descripción completa

Detalles Bibliográficos
Autores principales: Levine, Adrian, Li, Cyril, Haizel-Cobbina, Joseline, Nobre, Liana, Bennett, Julie, Dewan, Michael, Tabori, Uri, Hawkins, Cynthia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260182/
http://dx.doi.org/10.1093/neuonc/noad073.222
_version_ 1785057807761932288
author Levine, Adrian
Li, Cyril
Haizel-Cobbina, Joseline
Nobre, Liana
Bennett, Julie
Dewan, Michael
Tabori, Uri
Hawkins, Cynthia
author_facet Levine, Adrian
Li, Cyril
Haizel-Cobbina, Joseline
Nobre, Liana
Bennett, Julie
Dewan, Michael
Tabori, Uri
Hawkins, Cynthia
author_sort Levine, Adrian
collection PubMed
description Although most pediatric LGG (PLGG) have excellent long-term survival, there is a subset of cases that disseminate throughout the neuraxis (DLGG) that have very poor outcomes. The reason for this aggressive behavior is unknown but we hypothesize that distinct and specific biological mechanisms underlie the metastatic ability. The methylation-based class of diffuse leptomeningeal glioneuronal tumor (DLGNT) is characterized by MAPK pathway activating fusions with chromosome 1p loss, 19q loss, and/or 1q gain. However, it is unknown what proportion of DLGG match the DLGNT group, and which other methylations classes are at risk of metastasis. To improve our understanding of this rare patient population, we created an international DLGG consortium. Data from the first 68 cases shows a broad age distribution and no sex predilection. As expected, DLGG has much worse prognosis than the overall PLGG population. Virtually all DLGG progress at 5 years, compared to a quarter of other PLGG, and DLGG are 5-times more likely to die at 10 years. We observe three patterns of dissemination – 35% present with a localized mass and have secondary dissemination, 50% with disseminated tumor and a clear dominant mass, and 15% with disseminated disease without a dominant mass. In 47 patients with molecular testing, BRAF fusions accounted for 64% of driver alterations. Additional alterations were identified less frequently, including BRAF V600E (9%), FGFR1 alterations (9%), and KRAS mutations (4%). In 25 patients with methylation profiling, 10 (40%) successfully classified with a calibrated score above 0.8, illustrating that many cases do not fit a defined methylation group. The most common methylation classification was pilocytic astrocytoma (5 patients), and surprisingly only two patients classified as DLGNT. In sum this study illustrates the variable clinical behaviour associated with metastasis in PLGG and expands the range of molecular driver alterations, including ones previously unreported in DLGNT.
format Online
Article
Text
id pubmed-10260182
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-102601822023-06-13 LGG-12. CLINICAL AND MOLECULAR FEATURES OF DISSEMINATED PEDIATRIC LOW-GRADE GLIOMA Levine, Adrian Li, Cyril Haizel-Cobbina, Joseline Nobre, Liana Bennett, Julie Dewan, Michael Tabori, Uri Hawkins, Cynthia Neuro Oncol Final Category: Low Grade Gliomas - LGG Although most pediatric LGG (PLGG) have excellent long-term survival, there is a subset of cases that disseminate throughout the neuraxis (DLGG) that have very poor outcomes. The reason for this aggressive behavior is unknown but we hypothesize that distinct and specific biological mechanisms underlie the metastatic ability. The methylation-based class of diffuse leptomeningeal glioneuronal tumor (DLGNT) is characterized by MAPK pathway activating fusions with chromosome 1p loss, 19q loss, and/or 1q gain. However, it is unknown what proportion of DLGG match the DLGNT group, and which other methylations classes are at risk of metastasis. To improve our understanding of this rare patient population, we created an international DLGG consortium. Data from the first 68 cases shows a broad age distribution and no sex predilection. As expected, DLGG has much worse prognosis than the overall PLGG population. Virtually all DLGG progress at 5 years, compared to a quarter of other PLGG, and DLGG are 5-times more likely to die at 10 years. We observe three patterns of dissemination – 35% present with a localized mass and have secondary dissemination, 50% with disseminated tumor and a clear dominant mass, and 15% with disseminated disease without a dominant mass. In 47 patients with molecular testing, BRAF fusions accounted for 64% of driver alterations. Additional alterations were identified less frequently, including BRAF V600E (9%), FGFR1 alterations (9%), and KRAS mutations (4%). In 25 patients with methylation profiling, 10 (40%) successfully classified with a calibrated score above 0.8, illustrating that many cases do not fit a defined methylation group. The most common methylation classification was pilocytic astrocytoma (5 patients), and surprisingly only two patients classified as DLGNT. In sum this study illustrates the variable clinical behaviour associated with metastasis in PLGG and expands the range of molecular driver alterations, including ones previously unreported in DLGNT. Oxford University Press 2023-06-12 /pmc/articles/PMC10260182/ http://dx.doi.org/10.1093/neuonc/noad073.222 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Final Category: Low Grade Gliomas - LGG
Levine, Adrian
Li, Cyril
Haizel-Cobbina, Joseline
Nobre, Liana
Bennett, Julie
Dewan, Michael
Tabori, Uri
Hawkins, Cynthia
LGG-12. CLINICAL AND MOLECULAR FEATURES OF DISSEMINATED PEDIATRIC LOW-GRADE GLIOMA
title LGG-12. CLINICAL AND MOLECULAR FEATURES OF DISSEMINATED PEDIATRIC LOW-GRADE GLIOMA
title_full LGG-12. CLINICAL AND MOLECULAR FEATURES OF DISSEMINATED PEDIATRIC LOW-GRADE GLIOMA
title_fullStr LGG-12. CLINICAL AND MOLECULAR FEATURES OF DISSEMINATED PEDIATRIC LOW-GRADE GLIOMA
title_full_unstemmed LGG-12. CLINICAL AND MOLECULAR FEATURES OF DISSEMINATED PEDIATRIC LOW-GRADE GLIOMA
title_short LGG-12. CLINICAL AND MOLECULAR FEATURES OF DISSEMINATED PEDIATRIC LOW-GRADE GLIOMA
title_sort lgg-12. clinical and molecular features of disseminated pediatric low-grade glioma
topic Final Category: Low Grade Gliomas - LGG
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260182/
http://dx.doi.org/10.1093/neuonc/noad073.222
work_keys_str_mv AT levineadrian lgg12clinicalandmolecularfeaturesofdisseminatedpediatriclowgradeglioma
AT licyril lgg12clinicalandmolecularfeaturesofdisseminatedpediatriclowgradeglioma
AT haizelcobbinajoseline lgg12clinicalandmolecularfeaturesofdisseminatedpediatriclowgradeglioma
AT nobreliana lgg12clinicalandmolecularfeaturesofdisseminatedpediatriclowgradeglioma
AT bennettjulie lgg12clinicalandmolecularfeaturesofdisseminatedpediatriclowgradeglioma
AT dewanmichael lgg12clinicalandmolecularfeaturesofdisseminatedpediatriclowgradeglioma
AT taboriuri lgg12clinicalandmolecularfeaturesofdisseminatedpediatriclowgradeglioma
AT hawkinscynthia lgg12clinicalandmolecularfeaturesofdisseminatedpediatriclowgradeglioma